GRCE (Grace Therapeutics) Shiller PE Ratio: (As of Sep. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GRCE Grace Therapeutics Inc GRCE
33 GF Score
Price $2.10
! 2 Warning Signs
View Full Analysis

What is Grace Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Grace Therapeutics  (NAS:GRCE) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Grace Therapeutics Shiller PE Ratio Related Terms


Grace Therapeutics Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Grace Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grace Therapeutics Shiller PE Ratio Chart

Grace Therapeutics Annual Data
Trend Feb16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Grace Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GRCE vs VERU, TVGN, MGX: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Grace Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grace Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Grace Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Grace Therapeutics's Shiller PE Ratio falls into.


GRCE
33GF Score
Grace Therapeutics Inc GRCE
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grace Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Grace Therapeutics's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Grace Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.91/333.9520*333.9520
=-0.910

Current CPI (Jun. 2026) = 333.9520.

Grace Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201605 -10.673 240.229 -14.837
201608 -8.067 240.849 -11.185
201611 -7.860 241.353 -10.876
201706 -7.012 244.955 -9.560
201709 -11.995 246.819 -16.230
201712 -15.268 246.524 -20.683
201803 -11.364 249.554 -15.207
201806 -8.394 251.989 -11.124
201809 -23.034 252.439 -30.472
201812 -2.467 251.233 -3.279
201903 -8.609 254.202 -11.310
201906 -5.280 256.143 -6.884
201909 -12.000 256.759 -15.608
201912 -6.720 256.974 -8.733
202003 10.080 258.115 13.042
202006 -2.400 257.797 -3.109
202009 -3.120 260.280 -4.003
202012 -1.560 260.474 -2.000
202103 -1.301 264.877 -1.640
202106 -0.720 271.696 -0.885
202109 0.180 274.310 0.219
202112 -0.540 278.802 -0.647
202203 -0.529 287.504 -0.614
202206 -0.610 296.311 -0.687
202209 -0.660 296.808 -0.743
202212 -0.520 296.797 -0.585
202303 -3.910 301.836 -4.326
202306 -0.540 305.109 -0.591
202309 -0.430 307.789 -0.467
202312 -0.210 306.746 -0.229
202403 -0.260 312.332 -0.278
202406 -0.240 314.175 -0.255
202409 -0.300 315.301 -0.318
202412 -0.360 315.605 -0.381
202503 0.100 319.799 0.104
202506 -0.210 322.561 -0.217
202509 -0.060 324.800 -0.062
202512 -0.140 324.054 -0.144
202603 -0.060 330.213 -0.061
202606 -0.910 333.952 -0.910

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Grace Therapeutics Business Description

Address 103 Carnegie Center, Suite 300, Princeton, NJ, USA, 08540
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
33GF Score

Get the complete analysis for GRCE

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.10
Price